Will Garvin, shareholder in the firm's FDA & Biotechnology practice, provides detailed commentary on the Trump Administration's latest effort to address all-time-high out-of-pocket drug costs, possible effects of a newly proposed rule for price transparency in advertisements and the debate between pharmaceutical companies and the Department of Health and Human Services in Patient Engagement HIT's "Breaking Down HHS Drug Advertisement, Price Transparency Proposal."